A common implant designed to stimulate the spinal cord is enabling paralyzed patients to move again, a first-of-its-kind discovery in a clinical study at HCMC in Minneapolis. While findings have varied among the roughly 20 study participants, the upshot so far is that people can regain function after spinal cord injury and not simply maintain the limited mobility they have, said Dr. David Darrow, the principal investigator. The trial could be the first to force the US Food and Drug Administration to approve a device that restores function after spinal…
Read MoreTag: Trial
Largest Phase 3 Trial of Psilocybin for Depression Has Begun | Psychedelic spotlight
As our social fabric is unraveling and rates of depression continue to rise, affecting an estimated 310 million people worldwide, psilocybin research has given us a glimmer of hope that things may be changing for the better. The largest Phase 3 clinical trial investigating the safety, efficacy, and tolerability of psilocybin as a treatment for treatment-resistant depression (TRD) has finally begun. In late 2022, Compass Pathways announced that their Phase 3 program, consisting of two separate pivotal studies involving a total of 946 participants and one long-term follow-up study, would…
Read More